• Explore /
  • Poster
  • / Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

Abstract Poster

Authors

null

Nazli Dizman

City of Hope Comprehensive Cancer Center, Duarte, CA

Nazli Dizman , Jonathan E. Rosenberg , Jean H. Hoffman-Censits , David I. Quinn , Daniel Peter Petrylak , Matt D. Galsky , Ulka N. Vaishampayan , Ugo De Giorgi , Sumati Gupta , Howard A. Burris III, Harris S. Soifer , Gary Li , Carl L. Dambkowski , Susan Moran , Yining Ye , Siamak Daneshmand , Dean F. Bajorin , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT01004224

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4510)

DOI

10.1200/JCO.2019.37.15_suppl.4510

Abstract #

4510

Poster Bd #

336

Abstract Disclosures

Similar Posters

First Author: Yung Lyou

First Author: Yung Lyou

First Author: Petros Grivas

First Author: Kevin R Reyes